Meta-analysis

Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension

JAMA CardiolPublished

  • Systematic review and meta-analysis of randomised trials
  • random- and fixed-effects models

Authors' conclusion

The findings in the study showed that LDCs with 3 or 4 antihypertensives were an effective and well-tolerated BP-lowering treatment option for the initial or early management of hypertension.

Study context

Population
Patients with hypertension, initial management
Participants
1,918 patients · 7 RCTs
Comparison
Low-dose triple or quadruple combination pills vs monotherapy, usual care or placebo
Outcome
Mean reduction in SBP
Follow-up
4 to 12 weeks

Pooled result

As reported in the abstract

Mean reduction, mm Hg (95% CI)
LDC vs Monotherapy or usual care
7.4(4.3–10.5)
LDC vs Placebo
18.0(15.1–20.8)

Further pooled results

OutcomeLDCMonotherapy or usual carePlaceboRR (95% CI)
BP <140/90 mm Hg · 4 to 12 weeks — LDC vs Monotherapy or usual care66%46%Not reported in the abstract1.40 (1.27–1.52)
BP <140/90 mm Hg · 4 to 12 weeks — LDC vs Placebo54%Not reported in the abstract18%3.03 (1.93–4.77)

Heterogeneity by baseline blood pressure (BP)-lowering therapy

No significant heterogeneity between trials with and without baseline BP-lowering therapy

Systolic BP (SBP) reduction vs monotherapy or usual care (2 trials) · 6 to 12 months

Low-dose combination (LDC) remained superior to monotherapy or usual care

Safety

Dizziness

ComparisonRR (95% CI)
LDC · 14% vs 11%1.28 (1.00–1.63)

Other adverse effects and treatment withdrawal

No increase in other adverse effects or treatment withdrawal

Original publication

Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension. JAMA Cardiol. Published 1 June 2023. doi:10.1001/jamacardio.2023.0720

Summarised from the published abstract; every number is checked against it